Earnings Release • Oct 6, 2022
Earnings Release
Open in ViewerOpens in native device viewer
Paris, October 3rd, 2022
VISIOMED GROUP (FR0013481835– ALVMG), a group dedicated to innovative healthcare technologies and services, presents its revenue for the first half of 2022 and the operational and strategic decisions made for its two subsidiaries, Smart Salem and BewellConnect.
The first half of 2022 was a success. It was marked by a very strong consolidated revenue growth, the record growth of Smart Salem's core business (+66%), operational streamlining and the significant reduction of BewellConnect's fixed costs (-47%).
| As of June 30th - EURm (unaudited data) |
H1-2021 consolidated1 |
H1-2022 consolidated2 |
Change H1-21/22 |
|---|---|---|---|
| Smart Salem Revenue | 0.0 | 6.4 | +6.4 |
| BewellConnect Revenue | 0.3 | 2.4 | +2.1 |
| Consolidated Revenue | 0.3 | 8.8 | +8.5 |
Consolidated revenue for the first half of 2022 reached €8.8 million, i.e. +€8.5 million compared to consolidated revenue for the first half of 2021. This growth is mainly driven by:
Given Smart Salem was acquired in August 2021, the company is presenting a comparative analysis versus proforma revenue achieved in the first half of 2021.
| As of June 30th - EURm (unaudited data) | H1-2021 Proforma1 |
H1-20222 | Change H1-21/22 |
|---|---|---|---|
| Medical Fitness Revenue | 2.7 | 4.5 | +1.8 |
| COVID Revenue | 4.5 | 1.8 | (2.6) |
| Smart Salem Revenue | 7.2 | 6.4 | (0.8) |
1H1-2021 average exchange rate: EUR/AED = 4.4253
2H1-2022 average exchange rate: EUR/AED = 4.0120
Smart Salem's performance in the first half of 2022 is marked by:
As a reminder, and in line with its strategy to invest in « Medical Fitness » activities, Smart Salem continues to deliver on its development plan with:
| As of June 30th - EURm (unaudited data) | H1-2021 | H1-2022 | Change H1-21/22 |
|---|---|---|---|
| Connected Health Revenue | 0.3 | 0.0 | (0.2) |
| COVID Revenue | 0.0 | 2.3 | +2.3 |
| BewellConnect Revenue | 0.3 | 2.4 | +2.1 |
BewellConnect's revenue increased by +€2.1 million from the first half of 2021 to the first half of 2022, driven by:
As mentioned in previous communications, Management was keen to highlight the actions implemented for the future of BewellConnect.
The Management team appointed in April 2022 quickly reported the need for strong actions on BewellConnect to respond to recurring operational losses in connection with a poorly controlled cost structure and the complex functioning of the teams requiring a complete remobilization.
A plan to rationalize external expenses has been drawn up around two axes:
These actions have led to a significant reduction of BewellConnect's monthly fixed costs from €244 k in March 2022 to €129 k in September 2022, i.e. a decrease of 47%.
| Monthly reporting – EUR 000' (unaudited data) |
March 2022 | September 2022 |
Change (K€) | Change (%) |
|---|---|---|---|---|
| Staff costs | 85 | 53 | (32) | (37%) |
| R&D Expenses | 43 | 32 | (12) | (27%) |
| Other External Expenses | 115 | 44 | (72) | (63%) |
| Total Fixed Costs | 244 | 129 | (115) | (47%) |
This optimization plan, which began in the first half of 2022, will have a full impact on H2 2022 financials and offers more headroom to the Management team for targeted investments and recruitment.
At the same time, the assessment of commercial or equity partnerships continues.
Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.
The Group now has two wholly-owned subsidiaries:
BewellConnect offers an enriched technological universe, both in medical devices and software, making it possible to respond to all telehealth use cases: enriched and assisted teleconsultation, home telemonitoring, hospital monitoring, tele-expertise, teleassistance and tele-regulation.
BewellConnect's flagship product, VisioCheck, is the first telemedicine station weighing less than 300g for healthcare professionals, available in a case, station or modular health space.
BewellConnect is now deploying its solutions in France and abroad.
The Smart Salem offer is based on know-how in medical analysis, radiology and data analysis and processing to detect nearly 35 diseases in 7 minutes in a patient (in particular HIV, hepatitis and tuberculosis) by offering reliable results, readability and exceptional patient experience enabled by advanced artificial intelligence and virtual reality technologies.
Smart Salem's "Medical Fitness Assessment" offer resulting from this know-how thus makes it possible to obtain a residence or work visa in the space of 30 minutes compared to 10 to 15 days in historical health centers.
Smart Salem is a technological platform offering many growth opportunities, as shown by the opening of the second center in Dubai in September 2022 and the authorization received for the opening of a third center, planned to open in the first quarter of 2023.
Based in Paris, VISIOMED GROUP is listed on Euronext Growth (ALVMG). More information on visiomed.fr, smartsalem.ae and www.bewell-connect.com.


CONTACTS

Jérôme FABREGUETTES-LEIB Nawel NAAMANE
Phone: 01 53 67 36 78 Phone: 01 53 67 36 75
Investor Relations Financial Press Relations [email protected] [email protected]
© Visiomed Group SA 2022. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.